Search Weight Loss Topics:




Sep 30

Systemic Lupus Erythematosus: Competitive Analysis, Key Pharma Players and Emerging Therapy Report by DelveInsight – The Daily Chronicle

Long Term Weight Loss Comments Off on Systemic Lupus Erythematosus: Competitive Analysis, Key Pharma Players and Emerging Therapy Report by DelveInsight – The Daily Chronicle

Systemic lupus erythematosus, ( SLE, Lupus) is a chronic (long-term) disease that causes systemic inflammation which affects multiple organs. In addition to affecting the skin and joints, it can affect other organs in the body such as the kidneys, the tissue lining the lungs (pleura), heart (pericardium), and brain. Many patients experience fatigue, weight loss, and fever. Lupus flares vary from mild to severe. SLE is most commonly seen in women in the reproductive age group (frequently starting at childbearing age), although lupus is increasingly recognized after the age of 40 years, particularly in the Europeans.

The cause of lupus in most cases, however, is unknown. Some potential triggers include sunlight, genetic link, infections, and medicines. Common symptoms of SLE include tiredness, joint pain or swelling, fever, skin rash, mouth sores, and hair loss. In childhood-onset SLE, there are several clinical symptoms more commonly found than in adults, including malar rash, ulcer, renal involvement, proteinuria, seizures, thrombocytopenia, hemolytic anaemia, fever, and lymphadenopathy.

View report:https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight

Systemic Lupus Erythematosus Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Systemic Lupus Erythematosus market.

A detailed picture of the Systemic Lupus Erythematosus pipeline landscape is provided, which includes the disease overview and Systemic Lupus Erythematosus treatment guidelines. The assessment part of the report embraces in-depth Systemic Lupus Erythematosus commercial assessment and clinical assessment of the Systemic Lupus Erythematosus pipeline products from the pre-clinical developmental phase to the marketed phase.

Click here to request for sample pages.

Systemic Lupus Erythematosus Pipeline

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Systemic Lupus Erythematosus collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Anifrolumab (AstraZeneca), Lupuzor (ImmuPharma), Baricitinib (EliLilly), Stelara (JanssenPharmaceutical), Atacicept (MerckKGaA), ILT-101 (ILTOOPharma), BIIB059 (Biogen), CC-220 (Celgene), Dapirolizumab pegol (UCBPharma/Biogen), IFN Kinoid (Neovacs), Cenerimod (IdorsiaPharmaceuticals), KZR-616 (KezarLifeSciences), Lulizumab pegol (BristolMyersSquibb), XmAb5871 (Xencor), and others are currently under development for the treatment of SLE.

Scope of the report

Download free sample pages:https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight

Table of contents

AboutDelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.

Original post:
Systemic Lupus Erythematosus: Competitive Analysis, Key Pharma Players and Emerging Therapy Report by DelveInsight - The Daily Chronicle

Related Posts

    Your Full Name

    Your Email

    Your Phone Number

    Select your age (30+ only)

    Select Your US State

    Program Choice

    Confirm over 30 years old

    Yes

    Confirm that you resident in USA

    Yes

    This is a Serious Inquiry

    Yes

    Message:



    matomo tracker